IBD1
MCID: INF071
MIFTS: 68

Inflammatory Bowel Disease 1 (IBD1)

Categories: Blood diseases, Bone diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Inflammatory Bowel Disease 1

MalaCards integrated aliases for Inflammatory Bowel Disease 1:

Name: Inflammatory Bowel Disease 1 56 73
Inflammatory Bowel Disease 1 12 73 29 6 15
Crohn Disease 73 36 6 71
Crohn Disease-Associated Growth Failure 56 73 13
Ibd1 56 12 73
Crohn Disease-Associated Growth Failure, Susceptibility to 29 6
Inflammatory Bowel Disease 1, Crohn Disease 56 29
Ulcerative Colitis 73 71
Regional Enteritis 73 71
Bowel Disease, Inflammatory, Type 1 39

Characteristics:

OMIM:

56
Inheritance:
multifactorial

Miscellaneous:
genetic heterogeneity
5-10% of patients have a first degree relative with ibd (crohn or ulcerative colitis)
35% of cases involve ileum only (ileitis), 45% of cases involve ileum and colon (ileocolitis), 20% of cases involve colon alone - rectum spared (granulomatous colitis)


HPO:

31
inflammatory bowel disease 1:
Inheritance multifactorial inheritance heterogeneous


Classifications:



External Ids:

Disease Ontology 12 DOID:0110892
OMIM 56 266600
OMIM Phenotypic Series 56 PS266600
KEGG 36 H00286
UMLS 71 C0009324 C0010346 C0678202

Summaries for Inflammatory Bowel Disease 1

UniProtKB/Swiss-Prot : 73 Inflammatory bowel disease 1: A chronic, relapsing inflammation of the gastrointestinal tract with a complex etiology. It is subdivided into Crohn disease and ulcerative colitis phenotypes. Crohn disease may affect any part of the gastrointestinal tract from the mouth to the anus, but most frequently it involves the terminal ileum and colon. Bowel inflammation is transmural and discontinuous; it may contain granulomas or be associated with intestinal or perianal fistulas. In contrast, in ulcerative colitis, the inflammation is continuous and limited to rectal and colonic mucosal layers; fistulas and granulomas are not observed. Both diseases include extraintestinal inflammation of the skin, eyes, or joints.

MalaCards based summary : Inflammatory Bowel Disease 1, also known as inflammatory bowel disease 1, is related to pouchitis and cholangitis, primary sclerosing, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Inflammatory Bowel Disease 1 is NOD2 (Nucleotide Binding Oligomerization Domain Containing 2), and among its related pathways/superpathways are NOD-like receptor signaling pathway and Cytokine-cytokine receptor interaction. The drugs Tocopherol and Zinc have been mentioned in the context of this disorder. Affiliated tissues include colon, bone and t cells, and related phenotypes are abdominal pain and weight loss

Disease Ontology : 12 An inflammatory bowel disease that has material basis in mutations in the NOD2 gene on chromosome 16q12.1.

KEGG : 36 Crohn disease is a chronic, relapsing inflammatory bowel disease characterized by granulomatous inflammation, primarily localized to the terminal ileum. Most patients have involvement of the small intestine, but the other area of gastrointestinal tract may also be affected. In Western populations, over 50% of patients possess NOD2 mutations. Evidence exists that the NOD2 polymorphisms impair NF-kappaB activation and cytokine secretion in response to its ligand. The pathogenesis of Crohn's disease is also attributed to intestinal bacteria that may initiate mucosal inflammation in genetically susceptible individuals. Additional genes associated with the disease are recently being identified.

More information from OMIM: 266600 PS266600

Related Diseases for Inflammatory Bowel Disease 1

Diseases in the Inflammatory Bowel Disease family:

Inflammatory Bowel Disease 11 Inflammatory Bowel Disease 1
Inflammatory Bowel Disease 2 Inflammatory Bowel Disease 3
Inflammatory Bowel Disease 7 Inflammatory Bowel Disease 5
Inflammatory Bowel Disease 8 Inflammatory Bowel Disease 6
Inflammatory Bowel Disease 4 Inflammatory Bowel Disease 9
Inflammatory Bowel Disease 10 Inflammatory Bowel Disease 12
Inflammatory Bowel Disease 13 Inflammatory Bowel Disease 14
Inflammatory Bowel Disease 15 Inflammatory Bowel Disease 16
Inflammatory Bowel Disease 17 Inflammatory Bowel Disease 18
Inflammatory Bowel Disease 19 Inflammatory Bowel Disease 20
Inflammatory Bowel Disease 21 Inflammatory Bowel Disease 22
Inflammatory Bowel Disease 23 Inflammatory Bowel Disease 24
Inflammatory Bowel Disease 25, Autosomal Recessive Inflammatory Bowel Disease 26
Inflammatory Bowel Disease 27 Inflammatory Bowel Disease 28, Autosomal Recessive
Inflammatory Bowel Disease 29 Inflammatory Bowel Disease 28
Inflammatory Bowel Disease 25 Rare Inflammatory Bowel Disease

Diseases related to Inflammatory Bowel Disease 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1266)
# Related Disease Score Top Affiliating Genes
1 pouchitis 33.5 S100A9 NOD2
2 cholangitis, primary sclerosing 33.3 NOD2 IL6 CCR6
3 inflammatory bowel disease 19 33.3 NOD2 IRGM
4 ileitis 31.7 NOD2 IL6 CCR6 ATG16L1
5 spondylitis 31.4 NOD2 IL6 IL23R CCR6
6 spondyloarthropathy 1 31.3 S100A9 NOD2 IL23R CCR6
7 diverticulitis 31.3 TNFSF15 S100A9 IL6 CCR6
8 aortitis 31.2 NOD2 IL6
9 ileocolitis 31.1 PLA2G4F NOD2 ATG16L1
10 celiac disease 1 31.0 NOD2 IL6 IL23R CCR6 ATG16L1
11 inflammatory bowel disease 2 30.9 NOD2 ATG16L1
12 psoriatic arthritis 30.8 S100A9 NOD2 IL6 IL23R CCR6
13 bacterial infectious disease 30.8 NOD2 NOD1 IL6 CCR6
14 iritis 30.8 NOD2 IL6 CCR6
15 psoriasis 30.8 S100A9 NOD2 IL6 IL23R CCR6
16 inflammatory bowel disease 3 30.7 NOD2 IL23R
17 perinatal necrotizing enterocolitis 30.7 NOD2 IL6 CCR6
18 panuveitis 30.5 NOD2 IL6 CCR6
19 inflammatory bowel disease 18 30.5 NOD2 CCR6 ATG16L1
20 toxoplasmosis 30.5 NOD2 IRGM IL6
21 blau syndrome 30.5 RIPK2 NOD2 NOD1
22 aspergillosis 30.4 NOD2 IL6 CCR6
23 inflammatory bowel disease 8 30.4 NOD2 NOD1
24 inflammatory bowel disease 9 30.4 PLA2G4F NOD2
25 testicular disease 30.3 RIPK2 NOD2 IL6 CCR6
26 inflammatory bowel disease 6 30.3 NOD2 IL23R ATG16L1
27 tenosynovitis 30.1 NOD2 IL6
28 behcet syndrome 30.1 NOD2 IL6 IL23R CCR6
29 ulcerative colitis 29.9 TNFSF15 NOD2 IRGM IL6 IL23R CCR6
30 inflammatory bowel disease 5 29.9 TNFSF15 SLC22A5 SLC22A4 NOD2 IRGM IL23R
31 leprosy 3 29.8 TNFSF15 RIPK2 NOD2 IRGM IL6 IL23R
32 relapsing-remitting multiple sclerosis 29.8 IL6 IL23R CCR6
33 colitis 29.7 NOD2 NOD1 IRGM IL6 IL23R CCR6
34 inflammatory bowel disease 28.9 TNFSF15 SLC22A5 SLC22A4 S100A9 RIPK2 NOD2
35 crohn's disease 28.9 TNFSF15 SLC22A5 SLC22A4 S100A9 NOD2 NOD1
36 pediatric ulcerative colitis 12.6
37 obsolete: azathioprine dose selection in the treatment of crohn disease, leukemia and in transplantation 12.3
38 obsolete: mercaptopurine dose selection in the treatment of crohn disease, leukemia and in transplantation 12.3
39 ulcerative proctitis 11.9
40 colorectal cancer 11.8
41 irritable bowel syndrome 11.8
42 inflammatory bowel disease 17 11.7
43 inflammatory bowel disease 10 11.7
44 inflammatory bowel disease 25, autosomal recessive 11.7
45 pyoderma gangrenosum 11.7
46 colonic disease 11.7
47 bile duct cancer 11.6
48 colorectal cancer 10 11.6
49 chemical colitis 11.6
50 inflammatory bowel disease 14 11.4

Comorbidity relations with Inflammatory Bowel Disease 1 via Phenotypic Disease Network (PDN): (show all 11)


Active Peptic Ulcer Disease Acute Cystitis
Crohn's Disease Deficiency Anemia
Esophagitis Intestinal Obstruction
Iron Deficiency Anemia Osteoporosis
Paralytic Ileus Protein-Energy Malnutrition
Ulcerative Colitis

Graphical network of the top 20 diseases related to Inflammatory Bowel Disease 1:



Diseases related to Inflammatory Bowel Disease   1

Symptoms & Phenotypes for Inflammatory Bowel Disease 1

Human phenotypes related to Inflammatory Bowel Disease 1:

31 (show all 7)
# Description HPO Frequency HPO Source Accession
1 abdominal pain 31 HP:0002027
2 weight loss 31 HP:0001824
3 growth delay 31 HP:0001510
4 intestinal obstruction 31 HP:0005214
5 diarrhea 31 HP:0002014
6 recurrent aphthous stomatitis 31 HP:0011107
7 ulcerative colitis 31 HP:0100279

Symptoms via clinical synopsis from OMIM:

56
Abdomen Gastrointestinal:
abdominal pain
diarrhea
aphthous ulcers
bowel obstruction
strictures
more
Head And Neck Mouth:
aphthous ulcers (lips, gingiva, buccal mucosa)

Growth Weight:
weight loss

Clinical features from OMIM:

266600

UMLS symptoms related to Inflammatory Bowel Disease 1:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Inflammatory Bowel Disease 1:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.73 ATG16L1 CCR6 EPC1 IGSF6 IL23R IL6
2 digestive/alimentary MP:0005381 9.7 ATG16L1 IL23R IL6 NOD2 PRKCQ RIPK2
3 immune system MP:0005387 9.4 ATG16L1 CCR6 EPC1 IL23R IL6 NOD1

Drugs & Therapeutics for Inflammatory Bowel Disease 1

Drugs for Inflammatory Bowel Disease 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 488)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
2
Zinc Approved, Investigational Phase 4 7440-66-6 32051
3
Clarithromycin Approved Phase 4 81103-11-9 84029
4
Copper Approved, Investigational Phase 4 7440-50-8 27099
5
Clofazimine Approved, Investigational Phase 4 2030-63-9 2794
6
Rifabutin Approved, Investigational Phase 4 72559-06-9 6323490 46783538
7
Prucalopride Approved Phase 4 179474-81-8
8
Metronidazole Approved Phase 4 443-48-1 4173
9
Azithromycin Approved Phase 4 83905-01-5 55185 447043
10
Etidronic acid Approved Phase 4 2809-21-4, 7414-83-7 3305
11
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
12
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
13
Tofacitinib Approved, Investigational Phase 4 477600-75-2
14
Losartan Approved Phase 4 114798-26-4 3961
15
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
16
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
17
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
18
Caffeine Approved Phase 4 58-08-2 2519
19
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
20
Nicotine Approved Phase 4 54-11-5 942 89594
21
carbamide peroxide Approved Phase 4 124-43-6
22
Magnesium citrate Approved Phase 4 3344-18-1
23
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
24
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
25
Ondansetron Approved Phase 4 99614-02-5 4595
26
Vancomycin Approved Phase 4 1404-90-6 441141 14969
27
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
28
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
29
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
30
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
31
Racepinephrine Approved Phase 4 329-65-7 838
32
Sulfamethazine Approved, Investigational, Vet_approved Phase 4 57-68-1 5327
33
Ustekinumab Approved, Investigational Phase 4 815610-63-0
34
Certolizumab pegol Approved Phase 4 428863-50-7
35
tannic acid Approved Phase 4 1401-55-4
36
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
37
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
38
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
39
leucovorin Approved Phase 4 58-05-9 6006 143
40
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
41
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
42
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
43
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
44
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
45 Tocotrienol Investigational Phase 4 6829-55-6
46 Tocopherols Phase 4
47 Tocotrienols Phase 4
48 Cytochrome P-450 CYP3A Inhibitors Phase 4
49 Serotonin Agents Phase 4
50 Serotonin Receptor Agonists Phase 4

Interventional clinical trials:

(show top 50) (show all 2054)
# Name Status NCT ID Phase Drugs
1 Santeon InflixMab biosimILAr Research A Randomized, Controlled, Double Blind, Phase 4 Noninferiority Trial to Assess Efficacy of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission. Unknown status NCT02452151 Phase 4 Infliximab-Biosimilar;Infliximab-Innovator
2 Brief Escalation of Adalimumab Treatment for Prevention of Clinical Relapse in IBD Unknown status NCT03059849 Phase 4 Adalimumab
3 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) and Markers of Inflammation Unknown status NCT01765998 Phase 4 Probiotic;Placebo
4 PREDICT UC: Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis - A Randomised Controlled Trial Unknown status NCT02770040 Phase 4 Infliximab
5 Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative Colitis: An Open-label,Randomized,Phase IV Clinical Trial Unknown status NCT02962245 Phase 4 berberine;regular treatment
6 Fecal Microbiota Transplantation for Ulcerative Colitis Through Colonic Transendoscopic Enteral Tubing Unknown status NCT02998112 Phase 4 fecal microbiota transplantation;Saline
7 Combination Corticosteroids + 5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatment of Moderate-severe Active Ulcerative Colitis. Unknown status NCT01941589 Phase 4 oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone;corticosteroids only
8 Pilot Study to Evaluate the Efficacy of Golimumab for Induction and Maintenance of Clinical and Endoscopic Remission in Patients With Steroid-dependent Ulcerative Colitis Unknown status NCT02412085 Phase 4 Golimumab
9 A Randomized, Double-blind Study Investigating the Efficacy and Safety of Mesalazine With Hydrocortisone Sodium Succinate (100mg QD) Enema for 4-Week Treatment in Patients With Ulcerative Colitis (UC) Unknown status NCT03110198 Phase 4 Mesalazine;hydrocortisone sodium succinate;Mesalazine with hydrocortisone sodium succinate
10 Probiotic for the Restoration of Intestinal Permeability and Reduction of Intestinal Inflammation in Active Ulcerative Colitis: A Double Blind Randomized Placebo Controlled Trial Unknown status NCT01479660 Phase 4 Probiotic
11 Personalised Medicine: a Break Through Approach for Early Determination of Anti Tumor Necrosis Factor (TNF) Responders and Non Responders Among Patients With Ulcerative Colitis in a Prospective Study With Golimumab (Simponi) Unknown status NCT02186886 Phase 4 Golimumab
12 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease Unknown status NCT01632462 Phase 4 VSL#3
13 Randomized Cross-Over Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
14 Anemia Treatment in Inflammatory Bowel Disease: Predictive Factors of Response to Oral Iron Treatment Unknown status NCT02760940 Phase 4 oral liposomal iron
15 A Randomized, Controlled, Single-blind Study of Effects of Enteral Nutrition and Corticosteroid on Intestinal Flora in Induction Remission of Crohn Disease in Adult Unknown status NCT02056418 Phase 4 corticosteroid
16 Does Clinical Response Correlate With Serum Certolizumab Levels? A Prospective Open Label Trial of Adult Patients With Active Crohn's Disease (APOLLO) Unknown status NCT02597829 Phase 4 Certolizumab Pegol
17 Evaluation of PET CT in the Management of Patients With Crohn's Disease. Unknown status NCT00731809 Phase 4
18 Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease Unknown status NCT00609752 Phase 4 prednisolone
19 A Prospective Multi-centric Belgian Trial to Validate the Use of Golimumab Serum Level Analysis Using the Dried Blood Spot (DBS) Methodology Unknown status NCT02910375 Phase 4
20 Bacteria and Cytokines as Factors Modulating Visceral Afferent Processing in Irritable Bowel Syndrome: Manipulation of Intestinal Bacteria and Mucosal Cytokines by Probiotic Therapy and the Effect on Visceral Hypersensitivity Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
21 Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy Unknown status NCT00851565 Phase 4
22 Optimizing Response in Crohn's Disease Patients Who Have Insufficient Initial Response or Who Have Loss of Successful Response to Certolizumab Pegol (Cimzia) Induction Therapy Unknown status NCT01024647 Phase 4
23 The Effect of Probiotics on Bowel Disease Unknown status NCT01078935 Phase 4
24 Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission: A Multi-center, Double Blinded, Randomized, Placebo Controlled Study Unknown status NCT01817426 Phase 4 Infliximab
25 Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis Unknown status NCT00513552 Phase 4 Rifabutin, Clarithromycin, and Clofazimine
26 Phase IV Study Comparing a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis Unknown status NCT00265772 Phase 4 MODULEN IBD (R) (specific Enteral Nutrition);prednisolon
27 Double-blind Placebo Controlled Trial of VSL#3 in Children With Crohn's Disease Unknown status NCT00367705 Phase 4
28 The Effect of Prucalopride on Small Bowel Transit Time in Patients Undergoing Capsule Endoscopy: A Randomized Controlled Trial Unknown status NCT02806206 Phase 4 Prucalopride;Placebo
29 A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE AND CHRONIC PLAQUE PSORIASIS THE NOR-SWITCH STUDY Completed NCT02148640 Phase 4 Innovator infliximab;Biosimilar infliximab
30 An Open-Label, Multicenter and Open Enrollment Model, Postmarketing, Milk-Only Lactation Study to Assess Concentration of Vedolizumab in Breast Milk of Lactating Women With Active Ulcerative Colitis or Crohn's Disease Who Are Receiving Vedolizumab Therapeutically Completed NCT02559713 Phase 4 Vedolizumab
31 Serological Response to Pneumococcal Vaccination in Crohn's Disease: A Prospective Multicenter Study Completed NCT01505855 Phase 4 23-valent polysaccharide pneumococcal vaccine
32 Immunogenicity of Hepatitis A Vaccine in Patients With Inflammatory Bowel Disease Completed NCT01341808 Phase 4
33 Study for the Treatment of Ulcerative Colitis With Adacolumn (Companion to US Study 512-04-205) Completed NCT00219414 Phase 4
34 A Randomised Controlled Trial Comparing the Efficacy of Intravenous Iron Sucrose and Oral Iron Sulfate in Patients With Iron Deficiency. Completed NCT01067547 Phase 4 Iron Sucrose.;Iron sucrose
35 Preference for a Prefilled Syringe or Smartject™ Device for Delivering SIMPONI (Golimumab) in Patients Suffering From Moderate to Severe Ulcerative Colitis Completed NCT02155335 Phase 4 Prefilled Syringe delivery of Golimumab;Smartject Device delivery of Golimumab
36 Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease Completed NCT01034358 Phase 4
37 Multicentre Investigation of the Efficacy and Safety of Adacolumn® GMA in Patients With Steroid-Dependent Active Ulcerative Colitis and Insufficient Response or Intolerance to Immunosuppressants and/or Biological Therapies Completed NCT01481142 Phase 4
38 A Randomized, Multicenter Open Label Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis Completed NCT00542152 Phase 4 CYCLOSPORINE VS INFLIXIMAB
39 The Influence of 5–Aminosalicylates on Thiopurine Metabolite Levels Completed NCT00167882 Phase 4 5-aminosalicylate (Pentasa, Ferring)
40 Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease: A Prospective, Randomized, Double-Blind, Controlled Trial Completed NCT01346826 Phase 4 Standard 2 hours-infusion;Accelerated 1 hour-infusion;Accelerated 30 minutes-infusion
41 A Phase IV, Multi-center, Open-label Study to Assess Clinical Recurrence Related to Compliance With Treatment With MMX Mesalamine 2.4g/Day Given Once Daily for the Maintenance of Quiescent Ulcerative Colitis (UC) Completed NCT00446849 Phase 4 MMX Mesalamine
42 Golimumab: A Phase 4, UK, Open Label, Single Arm Study on Its Utilization and Impact in Ulcerative Colitis Completed NCT02092285 Phase 4 Golimumab
43 Active Ulcerative Colitis; Placebo Controlled Treatment Trial With Ciprofloxacin and E. Coli Nissle Completed NCT01772615 Phase 4 Ciprofloxacin
44 Histological and Endoscopic Evaluation of Remission Induced by Infliximab in Moderately to Severely Active Ulcerative Colitis Patients Completed NCT01408810 Phase 4 Infliximab
45 Treatment of Iron Deficiency Anaemia in Adults and Adolescents With Inflammatory Bowel Disease Using Ferrous Sulphate: Tolerance and Effects on Haemoglobin, Mood, Quality of Life and Fatigue Completed NCT01991314 Phase 4 Ferrous sulphate
46 Randomized, Double-Blind, Placebo-Controlled Study of VSL#3 Versus Placebo in the Maintenance of Remission in Crohn's Disease Completed NCT00114465 Phase 4 VSL#3
47 Test Treat Strategy to Prevent Ulcerative Colitis Relapse Completed NCT00652145 Phase 4 mesalamine
48 Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial Completed NCT02256462 Phase 4 Adalimumab
49 A Phase 4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term Maintenance Phase With 2.4g/Day MMX Mesalamine/Mesalazine Once Daily in Adult Subjects With Ulcerative Colitis Completed NCT01124149 Phase 4 MMX mesalamine/ mesalazine
50 Multi Center Ulcerative Colitis Pediatric Pentasa Intervention Trial (MUPPIT). A Randomized, Single-blinded, Controlled, Parallel, Induction Therapy With Once vs. Twice Daily Dosing of Pentasa in Pediatric UC. Completed NCT01201122 Phase 4 Mesalamine

Search NIH Clinical Center for Inflammatory Bowel Disease 1

Inferred drug relations via UMLS 71 / NDF-RT 50 :


aminosalicylic acid
Azathioprine
balsalazide
Balsalazide disodium
Cholecalciferol
Hydrocortisone
hydrocortisone acetate
HYDROCORTISONE ACETATE PWDR
HYDROCORTISONE ACETONIDE
Hydrocortisone butyrate
hydrocortisone cypionate
hydrocortisone probutate
HYDROCORTISONE PWDR
Hydrocortisone sodium phosphate
Hydrocortisone sodium succinate
hydrocortisone valerate
HYDROCORTISONE,NONSTERILE PWDR
mesalamine
natalizumab
nicotine polacrilex
olsalazine
Olsalazine sodium
Opium
OPIUM ALKALOIDS HYDROCHLORIDE
OPIUM, POWDERED
paregoric
Psyllium
PSYLLIUM HYDROCOLLOID
Sulfasalazine
Thalidomide

Genetic Tests for Inflammatory Bowel Disease 1

Genetic tests related to Inflammatory Bowel Disease 1:

# Genetic test Affiliating Genes
1 Inflammatory Bowel Disease 1 29 IL6
2 Inflammatory Bowel Disease 1, Crohn Disease 29
3 Crohn Disease-Associated Growth Failure, Susceptibility to 29

Anatomical Context for Inflammatory Bowel Disease 1

MalaCards organs/tissues related to Inflammatory Bowel Disease 1:

40
Colon, Bone, T Cells, Skin, Small Intestine, Lung, Testes

Publications for Inflammatory Bowel Disease 1

Articles related to Inflammatory Bowel Disease 1:

(show top 50) (show all 153)
# Title Authors PMID Year
1
Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the -174 IL-6 G/C polymorphism in children. 56 6
16150725 2005
2
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. 56 6
11385576 2001
3
Colonic epithelial cell diversity in health and inflammatory bowel disease. 56
30814735 2019
4
Fine-mapping inflammatory bowel disease loci to single-variant resolution. 56
28658209 2017
5
Ubiquitin Ligase TRIM62 Regulates CARD9-Mediated Anti-fungal Immunity and Intestinal Inflammation. 56
26488816 2015
6
NOD2-associated autoinflammatory disease: a large cohort study. 6
26070941 2015
7
Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. 56
25785968 2015
8
Paneth cells as a site of origin for intestinal inflammation. 56
24089213 2013
9
TGR5 signalling inhibits the production of pro-inflammatory cytokines by in vitro differentiated inflammatory and intestinal macrophages in Crohn's disease. 56
23566200 2013
10
Dermatitis as a characteristic phenotype of a new autoinflammatory disease associated with NOD2 mutations. 6
23102769 2013
11
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. 56
23128233 2012
12
Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. 56
22674328 2012
13
Dissecting the genetics of complex inheritance: linkage disequilibrium mapping provides insight into Crohn disease. 56
22152681 2011
14
Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. 56
21983784 2011
15
Genetics and pathogenesis of inflammatory bowel disease. 56
21677747 2011
16
Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease. 56
21151126 2011
17
A new category of autoinflammatory disease associated with NOD2 gene mutations. 6
21914217 2011
18
Analysis of SNPs with an effect on gene expression identifies UBE2L3 and BCL3 as potential new risk genes for Crohn's disease. 56
20601676 2010
19
Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease. 56
20570966 2010
20
Comparative genetic analysis of inflammatory bowel disease and type 1 diabetes implicates multiple loci with opposite effects. 56
20176734 2010
21
Genome-wide association study for ulcerative colitis identifies risk loci at 7q22 and 22q13 (IL17REL). 56
20228798 2010
22
Genome-wide association identifies multiple ulcerative colitis susceptibility loci. 56
20228799 2010
23
NOD2-associated diseases: Bridging innate immunity and autoinflammation. 6
19467619 2010
24
A genome-wide association study identifies three new susceptibility loci for ulcerative colitis in the Japanese population. 56
19915573 2009
25
Inflammatory bowel disease. 56
19923578 2009
26
Diverse genome-wide association studies associate the IL12/IL23 pathway with Crohn Disease. 56
19249008 2009
27
rs224136 on chromosome 10q21.1 and variants in PHOX2B, NCF4, and FAM92B are not major genetic risk factors for susceptibility to Crohn's disease in the German population. 56
19262523 2009
28
Confirmation of multiple Crohn's disease susceptibility loci in a large Dutch-Belgian cohort. 56
19174780 2009
29
Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. 56
19122664 2009
30
Investigation of Crohn's disease risk loci in ulcerative colitis further defines their molecular relationship. 56
19068216 2009
31
Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. 56
19098911 2009
32
Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. 56
18836448 2008
33
Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease. 56
18422560 2008
34
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. 56
18587394 2008
35
Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. 56
18438405 2008
36
Genetic analysis of innate immunity in Crohn's disease and ulcerative colitis identifies two susceptibility loci harboring CARD9 and IL18RAP. 56
18439550 2008
37
An SNP linkage scan identifies significant Crohn's disease loci on chromosomes 13q13.3 and, in Jewish families, on 1p35.2 and 3q29. 56
18246054 2008
38
New links to the pathogenesis of Crohn disease provided by genome-wide association scans. 56
17968351 2008
39
The genetics of inflammatory bowel disease. 56
17919503 2007
40
Interleukin-6 genetic variability and adiposity: associations in two prospective cohorts and systematic review in 26,944 individuals. 6
17623760 2007
41
Genome-wide association study for Crohn's disease in the Quebec Founder Population identifies multiple validated disease loci. 56
17804789 2007
42
Increased expression and activation of IL-12-induced Stat4 signaling in the mucosa of ulcerative colitis patients. 56
18048021 2007
43
Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. 56
17554261 2007
44
CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. 56
17525800 2007
45
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. 56
17554300 2007
46
Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. 56
17435756 2007
47
Inflammatory bowel disease: cause and immunobiology. 56
17499605 2007
48
Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. 56
17447842 2007
49
Epithelial NEMO links innate immunity to chronic intestinal inflammation. 56
17361131 2007
50
Aberrant intestinal expression and allelic variants of mucin genes associated with inflammatory bowel disease. 56
17058067 2006

Variations for Inflammatory Bowel Disease 1

ClinVar genetic disease variations for Inflammatory Bowel Disease 1:

6 (show top 50) (show all 183) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 HSPA1L NM_005527.4(HSPA1L):c.1673A>C (p.Glu558Ala)SNV association 372131 rs2227955 6:31778077-31778077 6:31810300-31810300
2 HSPA1L NM_005527.4(HSPA1L):c.802G>A (p.Ala268Thr)SNV association 372132 rs34620296 6:31778948-31778948 6:31811171-31811171
3 HSPA1L NM_005527.4(HSPA1L):c.800C>T (p.Thr267Ile)SNV association 372133 rs139868987 6:31778950-31778950 6:31811173-31811173
4 HSPA1L NM_005527.4(HSPA1L):c.515_517del (p.Leu172del)deletion association 372135 rs750447828 6:31779233-31779235 6:31811456-31811458
5 HSPA1L NM_005527.4(HSPA1L):c.229G>A (p.Gly77Ser)SNV association 372134 rs368138379 6:31779521-31779521 6:31811744-31811744
6 NOD2 NM_022162.3(NOD2):c.1001G>A (p.Arg334Gln)SNV Pathogenic 4694 rs104895461 16:50744823-50744823 16:50710912-50710912
7 NOD2 NM_022162.3(NOD2):c.1000C>T (p.Arg334Trp)SNV Pathogenic 4696 rs104895462 16:50744822-50744822 16:50710911-50710911
8 NOD2 NM_022162.3(NOD2):c.1147G>A (p.Glu383Lys)SNV Pathogenic 4701 rs104895477 16:50744969-50744969 16:50711058-50711058
9 NOD2 NM_022162.3(NOD2):c.1538T>C (p.Met513Thr)SNV Pathogenic 97834 rs104895473 16:50745360-50745360 16:50711449-50711449
10 NOD2 NM_022162.3(NOD2):c.1720C>T (p.Gln574Ter)SNV Pathogenic 634817 rs1264862631 16:50745542-50745542 16:50711631-50711631
11 PRKCQ NM_006257.5(PRKCQ):c.989C>T (p.Pro330Leu)SNV Pathogenic 586982 rs2236379 10:6527143-6527143 10:6485181-6485181
12 NOD2 NM_022162.3(NOD2):c.2555A>G (p.Asn852Ser)SNV risk factor 97856 rs104895467 16:50750810-50750810 16:50716899-50716899
13 IL6 IL6, -174G-CSNV risk factor 14718
14 NOD2 NM_022162.3(NOD2):c.3019dup (p.Leu1007fs)duplication risk factor 4691 rs2066847 16:50763778-50763779 16:50729867-50729868
15 NOD2 NM_022162.3(NOD2):c.2722G>C (p.Gly908Arg)SNV risk factor 4692 rs2066845 16:50756540-50756540 16:50722629-50722629
16 NOD2 NM_022162.3(NOD2):c.2104C>T (p.Arg702Trp)SNV risk factor 4693 rs2066844 16:50745926-50745926 16:50712015-50712015
17 NOD2 NM_022162.3(NOD2):c.1281G>A (p.Pro427=)SNV Conflicting interpretations of pathogenicity 97825 rs104895430 16:50745103-50745103 16:50711192-50711192
18 NOD2 NM_022162.3(NOD2):c.2107C>T (p.Arg703Cys)SNV Conflicting interpretations of pathogenicity 197333 rs5743277 16:50745929-50745929 16:50712018-50712018
19 NOD2 NM_022162.3(NOD2):c.1509G>A (p.Glu503=)SNV Conflicting interpretations of pathogenicity 97833 rs104895434 16:50745331-50745331 16:50711420-50711420
20 NOD2 NM_022162.3(NOD2):c.413G>A (p.Arg138Gln)SNV Conflicting interpretations of pathogenicity 97877 rs104895456 16:50733738-50733738 16:50699827-50699827
21 NOD2 NM_022162.3(NOD2):c.703C>T (p.Arg235Cys)SNV Conflicting interpretations of pathogenicity 97879 rs104895422 16:50744525-50744525 16:50710614-50710614
22 NOD2 NM_022162.3(NOD2):c.74-7T>ASNV Conflicting interpretations of pathogenicity 97880 rs104895421 16:50733392-50733392 16:50699481-50699481
23 NOD2 NM_022162.3(NOD2):c.931C>T (p.Arg311Trp)SNV Conflicting interpretations of pathogenicity 97885 rs104895427 16:50744753-50744753 16:50710842-50710842
24 NOD2 NM_022162.3(NOD2):c.807G>A (p.Pro269=)SNV Conflicting interpretations of pathogenicity 319436 rs369766454 16:50744629-50744629 16:50710718-50710718
25 NOD2 NM_022162.3(NOD2):c.484G>A (p.Val162Ile)SNV Conflicting interpretations of pathogenicity 319427 rs139571975 16:50733809-50733809 16:50699898-50699898
26 NOD2 NM_022162.3(NOD2):c.566C>T (p.Thr189Met)SNV Conflicting interpretations of pathogenicity 319431 rs61755182 16:50741791-50741791 16:50707880-50707880
27 NOD2 NM_022162.3(NOD2):c.2546C>T (p.Ala849Val)SNV Conflicting interpretations of pathogenicity 97855 rs104895486 16:50750581-50750581 16:50716670-50716670
28 NOD2 NM_022162.3(NOD2):c.2003C>T (p.Pro668Leu)SNV Conflicting interpretations of pathogenicity 319456 rs5743275 16:50745825-50745825 16:50711914-50711914
29 NOD2 NM_022162.3(NOD2):c.841C>T (p.Leu281Phe)SNV Conflicting interpretations of pathogenicity 319438 rs756943416 16:50744663-50744663 16:50710752-50710752
30 NOD2 NM_022162.3(NOD2):c.1316G>A (p.Arg439His)SNV Conflicting interpretations of pathogenicity 319444 rs143110172 16:50745138-50745138 16:50711227-50711227
31 NOD2 NM_022162.3(NOD2):c.1603C>T (p.Leu535=)SNV Conflicting interpretations of pathogenicity 319447 rs145190613 16:50745425-50745425 16:50711514-50711514
32 NOD2 NM_022162.3(NOD2):c.1834G>T (p.Ala612Ser)SNV Conflicting interpretations of pathogenicity 319452 rs104895438 16:50745656-50745656 16:50711745-50711745
33 NOD2 NM_022162.3(NOD2):c.2330C>A (p.Thr777Asn)SNV Uncertain significance 319463 rs756184386 16:50746152-50746152 16:50712241-50712241
34 NOD2 NM_022162.3(NOD2):c.2365C>T (p.Leu789Phe)SNV Uncertain significance 319464 rs773758818 16:50746187-50746187 16:50712276-50712276
35 NOD2 NM_022162.3(NOD2):c.2494A>G (p.Ile832Val)SNV Uncertain significance 319468 rs765335094 16:50750529-50750529 16:50716618-50716618
36 NOD2 NM_022162.3(NOD2):c.2740G>A (p.Glu914Lys)SNV Uncertain significance 319473 rs758913334 16:50756558-50756558 16:50722647-50722647
37 NOD2 NM_022162.3(NOD2):c.*186C>GSNV Uncertain significance 319477 rs886052045 16:50765916-50765916 16:50732005-50732005
38 NOD2 NM_022162.3(NOD2):c.*422C>GSNV Uncertain significance 319483 rs886052049 16:50766152-50766152 16:50732241-50732241
39 NOD2 NM_022162.3(NOD2):c.2632C>T (p.Leu878=)SNV Uncertain significance 319470 rs886052044 16:50753837-50753837 16:50719926-50719926
40 NOD2 NM_022162.3(NOD2):c.*873C>TSNV Uncertain significance 319488 rs373812846 16:50766603-50766603 16:50732692-50732692
41 NOD2 NM_022162.3(NOD2):c.1856C>T (p.Ala619Val)SNV Uncertain significance 319454 rs867131858 16:50745678-50745678 16:50711767-50711767
42 NOD2 NM_022162.3(NOD2):c.*1201T>ASNV Uncertain significance 319493 rs751525993 16:50766931-50766931 16:50733020-50733020
43 NOD2 NM_022162.3(NOD2):c.140C>T (p.Ser47Leu)SNV Uncertain significance 319424 rs201586544 16:50733465-50733465 16:50699554-50699554
44 NOD2 NM_022162.3(NOD2):c.1634C>T (p.Pro545Leu)SNV Uncertain significance 319448 rs777949388 16:50745456-50745456 16:50711545-50711545
45 NOD2 NM_022162.3(NOD2):c.1540T>C (p.Tyr514His)SNV Uncertain significance 449632 rs540122692 16:50745362-50745362 16:50711451-50711451
46 NOD2 NM_022162.3(NOD2):c.2038G>A (p.Gly680Arg)SNV Uncertain significance 462698 rs371339573 16:50745860-50745860 16:50711949-50711949
47 NOD2 NM_022162.3(NOD2):c.127G>A (p.Glu43Lys)SNV Uncertain significance 462695 rs200089552 16:50733452-50733452 16:50699541-50699541
48 NOD2 NM_022162.3(NOD2):c.7G>C (p.Glu3Gln)SNV Uncertain significance 531610 rs976567823 16:50731161-50731161 16:50697250-50697250
49 NOD2 NM_022162.3(NOD2):c.314C>T (p.Ala105Val)SNV Uncertain significance 531606 rs202052365 16:50733639-50733639 16:50699728-50699728
50 NOD2 NM_022162.3(NOD2):c.698A>C (p.Gln233Pro)SNV Uncertain significance 531596 rs369098290 16:50744520-50744520 16:50710609-50710609

UniProtKB/Swiss-Prot genetic disease variations for Inflammatory Bowel Disease 1:

73
# Symbol AA change Variation ID SNP ID
1 NOD2 p.Arg702Trp VAR_012689 rs2066844
2 NOD2 p.Gly908Arg VAR_012701 rs2066845

Expression for Inflammatory Bowel Disease 1

Search GEO for disease gene expression data for Inflammatory Bowel Disease 1.

Pathways for Inflammatory Bowel Disease 1

Pathways related to Inflammatory Bowel Disease 1 according to KEGG:

36
# Name Kegg Source Accession
1 NOD-like receptor signaling pathway hsa04621
2 Cytokine-cytokine receptor interaction hsa04060
3 JAK-STAT signaling pathway hsa04630
4 Inflammatory bowel disease (IBD) hsa05321
5 Autophagy - animal hsa04140

GO Terms for Inflammatory Bowel Disease 1

Biological processes related to Inflammatory Bowel Disease 1 according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.99 S100A9 RIPK2 NOD2 NOD1 IRGM IL23R
2 immune system process GO:0002376 9.95 S100A9 RIPK2 PRKCQ NOD2 NOD1 IRGM
3 defense response to bacterium GO:0042742 9.94 S100A9 NOD2 NOD1 IRGM
4 cellular response to lipopolysaccharide GO:0071222 9.89 RIPK2 NOD2 IRGM IL6
5 defense response to Gram-positive bacterium GO:0050830 9.83 RIPK2 NOD1 IL6
6 interleukin-1-mediated signaling pathway GO:0070498 9.83 RIPK2 NOD2 NOD1
7 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.83 TNFSF15 S100A9 NOD1
8 defense response to Gram-negative bacterium GO:0050829 9.82 IRGM IL6 IL23R
9 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.81 RIPK2 IRGM IL6
10 positive regulation of JNK cascade GO:0046330 9.81 RIPK2 NOD2 NOD1
11 positive regulation of T cell proliferation GO:0042102 9.79 PRKCQ IL6 IL23R
12 positive regulation of tumor necrosis factor production GO:0032760 9.74 RIPK2 NOD2 NOD1
13 JNK cascade GO:0007254 9.73 RIPK2 NOD2 NOD1
14 positive regulation of interleukin-1 beta production GO:0032731 9.66 NOD2 NOD1
15 detection of bacterium GO:0016045 9.63 NOD2 NOD1
16 nucleotide-binding oligomerization domain containing signaling pathway GO:0070423 9.63 RIPK2 NOD2 NOD1
17 positive regulation of T-helper 1 type immune response GO:0002827 9.62 RIPK2 IL23R
18 leukocyte migration involved in inflammatory response GO:0002523 9.62 S100A9 CCR6
19 positive regulation of interleukin-6 production GO:0032755 9.62 RIPK2 NOD2 NOD1 IL6
20 positive regulation of T-helper 17 type immune response GO:2000318 9.61 PRKCQ IL23R
21 positive regulation of stress-activated MAPK cascade GO:0032874 9.61 RIPK2 NOD2 NOD1
22 positive regulation of dendritic cell antigen processing and presentation GO:0002606 9.6 NOD2 NOD1
23 positive regulation of xenophagy GO:1904417 9.58 RIPK2 NOD1
24 cellular response to peptidoglycan GO:0071224 9.58 RIPK2 NOD2
25 carnitine transport GO:0015879 9.55 SLC22A5 SLC22A4
26 protein lipidation involved in autophagosome assembly GO:0061739 9.54 IRGM ATG16L1
27 positive regulation of interleukin-17 production GO:0032740 9.54 PRKCQ NOD2 IL23R
28 quaternary ammonium group transport GO:0015697 9.52 SLC22A5 SLC22A4
29 inflammatory response GO:0006954 9.5 S100A9 RIPK2 PRKCQ NOD1 IRGM IL6
30 carnitine transmembrane transport GO:1902603 9.49 SLC22A5 SLC22A4
31 detection of biotic stimulus GO:0009595 9.48 NOD2 NOD1
32 cellular response to muramyl dipeptide GO:0071225 9.43 RIPK2 NOD2 NOD1
33 nucleotide-binding oligomerization domain containing 2 signaling pathway GO:0070431 9.33 RIPK2 NOD2 IRGM
34 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.1 S100A9 RIPK2 PRKCQ NOD2 NOD1 IL6

Molecular functions related to Inflammatory Bowel Disease 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.87 SLC22A5 SLC22A4 RIPK2 PRKCQ NOD2 NOD1
2 peptidoglycan binding GO:0042834 9.26 NOD2 NOD1
3 quaternary ammonium group transmembrane transporter activity GO:0015651 9.16 SLC22A5 SLC22A4
4 carnitine transmembrane transporter activity GO:0015226 8.96 SLC22A5 SLC22A4
5 CARD domain binding GO:0050700 8.92 RIPK2 NOD2 NOD1 IRGM

Sources for Inflammatory Bowel Disease 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....